Cancer Therapy News and Research

RSS

Scientists provide new insight into mechanisms controlling programmed cell death pathways

Work led by St. Jude Children's Research Hospital investigators provides fresh insight into mechanisms controlling programmed cell death pathways and offers new targets in the fight against cancer and virus-infected cells

3 Mar 2011

New microfluidic device may help clinicians to improve cancer therapy

Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.

3 Mar 2011

K-State chemistry professor receives Sloan Foundation Fellowship for gold nanoparticle research

A Kansas State University chemistry professor has been selected as a Sloan Research Fellow for her success as a promising young scholar, particularly in the research areas of sustainable energy and gold nanoparticles.

1 Mar 2011

Chromosomally unstable bowel cancer cells more resistant to chemotherapy treatments, targeted drugs

Cancer Research UK scientists have made an important step towards developing personalised bowel cancer treatment by identifying which tumours are more likely to become drug resistant, according to research published in Cancer Research today.

1 Mar 2011

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

1 Mar 2011

HCI creates Pediatric Cancer Late Effects Clinic to help manage long-term issues of treatment

Although cancer in children is rare, more than 10,000 children in the United States are diagnosed with some form of the disease every year. If these children survive, studies have found that more than two-thirds develop at least one late-effect of treatment, which can include additional cancers, fertility and heart problems, limited limb function, and hearing loss.

1 Mar 2011

Researcher identifies substance that inhibits cancer growth by activating 'dark genome'

A research study coordinated by Manel Esteller, researcher at Bellvitge Biomedical Research Institute (IDIBELL) has identified a substance that inhibits cancer growth by activating the so‑called "dark genome" (or non‑coding DNA) and micro‑RNA molecules. The study appears this week in the journal Proceedings of the National Academy of Sciences (PNAS).

1 Mar 2011

p53 gene blocks EMT essential to cancer metastasis

Like a bounty hunter returning escapees to custody, a cancer-fighting gene converts organ cells that change into highly mobile stem cells back to their original, stationary state, researchers report online at Nature Cell Biology.

28 Feb 2011

Avastin debate spills over until June FDA hearing

The U.S. Food and Drug Administration have granted Roche a hearing in June to defend the cancer treatment Avastin. The hearing would examine the effectiveness of the drug in breast cancer.

27 Feb 2011

Eigen ei-Nav|Artemis system for prostate biopsy installed at Smilow Comprehensive Prostate Cancer Center

As a world leader in the advancement of the detection and treatment of prostate cancer, the Smilow Comprehensive Prostate Cancer Center at NYU Langone Medical Center is the first medical facility in the Northeast to install ei-Nav|Artemis™, an innovative image guidance and navigation system for prostate biopsy that is manufactured by Eigen.

25 Feb 2011

BSD announces inclusion of hyperthermia and chemotherapy for high-risk sarcoma cancer patients

BSD Medical Corporation today announced the inclusion of hyperthermia and chemotherapy as a recommended cancer treatment for Stage IV sarcomas in the "Practice Guidelines in Oncology", which is issued by the National Comprehensive Cancer Network.

25 Feb 2011

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

24 Feb 2011

ViewRay's radiotherapy treatment planning and delivery software receives FDA marketing clearance

ViewRay™, Inc., a privately held medical device company, has received U.S. FDA marketing clearance for its radiotherapy treatment planning and delivery software.

24 Feb 2011

MD Anderson physician honored for impact on blood, marrow transplantation

The American Society for Blood and Marrow Transplantation has honored leader, innovator and educator Richard Champlin, M.D., with its Lifetime Achievement Award during the group's annual meeting Feb. 17-21.

23 Feb 2011

Cannabis Science extract treatments help kill cancer cells

Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells.

23 Feb 2011

Mechanism of cancer treatment related to infertility in women

Chemotherapeutic agents, used in cancer treatment, destroy not only cancer cells but also healthy cells, thus affecting germ cells as well. Consequently, after surviving cancer many female patients are confronted with the diagnosis: infertility. For a long time a relationship between infertility and chemotherapeutic agents has been assumed, but until now, the exact mechanism was not known.

23 Feb 2011

Research: Drug developed for controlling cholesterol synthesis can kill human breast cancer cells

A University of Missouri researcher believes there could be a new drug compound that could kill breast cancer cells. The compound might also help with controlling cholesterol.

23 Feb 2011

Commentary examines current guidelines for cancer survivors, suggests future nutrition research

Cancer survivors die of non-cancer-related causes at much higher rates than the general public. In 2008, the U.S. economic burden of cancer totaled over $228 billion but only 41% of these costs involved direct cancer care. The majority of expenses were attributed to increased morbidity, lost productivity, and premature mortality.

18 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

Viewpoints: Arizona's waiver; next gen's 'different' Medicare?; individual mandate's constitutionality

There may be no federal obstacles to cutting 250,000 people out of AHCCCS, part of Gov. Jan Brewer's budget proposal. But there are compelling reasons to avoid such a drastic step if at all possible. And it's possible.

17 Feb 2011

Cancer Therapy News and Research

Scientists provide new insight into mechanisms controlling programmed cell death pathways

New microfluidic device may help clinicians to improve cancer therapy

K-State chemistry professor receives Sloan Foundation Fellowship for gold nanoparticle research

Chromosomally unstable bowel cancer cells more resistant to chemotherapy treatments, targeted drugs

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

HCI creates Pediatric Cancer Late Effects Clinic to help manage long-term issues of treatment

Researcher identifies substance that inhibits cancer growth by activating 'dark genome'

p53 gene blocks EMT essential to cancer metastasis

Avastin debate spills over until June FDA hearing

Eigen ei-Nav|Artemis system for prostate biopsy installed at Smilow Comprehensive Prostate Cancer Center

BSD announces inclusion of hyperthermia and chemotherapy for high-risk sarcoma cancer patients

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

ViewRay's radiotherapy treatment planning and delivery software receives FDA marketing clearance

MD Anderson physician honored for impact on blood, marrow transplantation

Cannabis Science extract treatments help kill cancer cells

Mechanism of cancer treatment related to infertility in women

Research: Drug developed for controlling cholesterol synthesis can kill human breast cancer cells

Commentary examines current guidelines for cancer survivors, suggests future nutrition research

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Viewpoints: Arizona's waiver; next gen's 'different' Medicare?; individual mandate's constitutionality

Your guide to microplate readers for cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News